Structure and Function of Human Prepro-orexin Gene*

Takeshi SakuraiDagger §, Takashi MoriguchiDagger , Keiko Furuya, Noriko Kajiwara, Toshiaki NakamuraDagger , Masashi Yanagisawaparallel , and Katsutoshi GotoDagger

From the Dagger  Institute of Basic Medical Sciences,  Laboratory Animal Research Center, University of Tsukuba, Tsukuba, Ibaraki, 305-8575, Japan and the parallel  Howard Hughes Medical Institute and Department of Molecular Genetics, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235-9050

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Orexin-A and -B are recently identified potent orexigenic peptides that are derived from the same precursor peptide and are highly specifically localized in neurons located in the lateral hypothalamic area, a region classically implicated in feeding behavior. We cloned the whole length of the human prepro-orexin gene and corresponding cDNA. The human prepro-orexin mRNA was predicted to encode a 131-residue precursor peptide (prepro-orexin). The human prepro-orexin gene consists of two exons and one intron distributed over 1432 base pairs. The 143-base pair first exon includes the 5'-untranslated region and a small part of the coding region that encodes the first seven residues of the secretory signal sequence. The second exon contains the remaining portion of the open reading frame and 3'-untranslated region. The 3.2 kilobase pairs of the 5'-upstream region from a cloned human prepro-orexin gene promoter is sufficient to direct the expression of the Escherichia coli beta -galactosidase (lacZ) gene in transgenic mice to neurons in the lateral hypothalamic area and adjacent regions. The lacZ-positive neurons were positively stained with anti-orexin antibody but not with anti-melanin-concentrating hormone antibody. These findings suggest that this genomic fragment contains all the necessary elements for appropriate expression of the gene and will be useful for the targeted expression of the exogenous gene in orexin-containing neurons. These mice might also be useful for examining the molecular mechanisms by which orexin gene expression is regulated.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Orexins (orexin-A and -B) are neuropeptides that were identified as endogenous ligands for an orphan G-protein-coupled receptor, which was originally found as an expressed sequence tag from human brain (1). Orexin-A and -B are derived from the same precursor peptide (prepro-orexin) by proteolytic processing. They bind and activate two closely related G-protein-coupled receptors, termed OX1 and OX2 receptors. OX1 receptor is selective for orexin-A, whereas OX2 receptor is a nonselective receptor for both orexin-A and -B. Prepro-orexin mRNA and immunoreactive orexin-A are highly specifically localized in neurons within and around the lateral hypothalamic area (LHA)1 in the adult rat brain, a region implicated in feeding behavior (2-4). Orexin-containing neurons diffusely innervate the entire brain, including monosynaptic projections, to various regions of the cerebral cortex, limbic system, and brain stem (5, 6). Orexins stimulate food consumption when administered intracerebroventricularly (1). Orexin gene expression is up-regulated upon fasting, suggesting the existence of molecular mechanisms that control orexin gene expression according to the nutritional status of the animal (1).

Expression of the orexin gene is highly restricted to neurons located in the LHA, indicating the existence of molecular mechanisms by which orexin gene transcription is highly specifically performed by the distinct population of neurons in these areas (1, 5, 7). Radiation hybrid mapping showed that the human prepro-orexin gene is located at human chromosome 17q21 (1). We have already reported that human prepro-orexin mRNA can also be exclusively detected in the hypothalamus/subthalamic regions (1). The mechanisms by which orexin gene expression is highly restricted to the distinct populations of neurons in these regions is of interest.

As the first step toward unveiling these mechanisms, we cloned fragments of the human prepro-orexin gene and its corresponding cDNA to determine their complete primary structures. One way to study the physiological roles of the orexin neuronal system would be to examine the consequences of expression of exogenous genes in orexin-producing neurons of transgenic mice, thereby manipulating the cellular environment in vivo. However, such studies require the use of an appropriate gene promoter to direct gene expression to orexin-producing neurons. Human prepro-orexin gene promoter is indeed a good candidate for targeting gene expression to orexin-producing neurons.

From these points of view, we made a prepro-orexin-lacZ fusion gene and tested it in transgenic mice to identify a DNA fragment containing all the necessary elements for appropriate orexin expression. This approach would also be useful to examine the mechanism by which orexin gene expression is highly restricted to the LHA and adjacent regions.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning of Human Prepro-orexin Gene-- Because we found that the full-length rat orexin cDNA, which contains CTG triplet repeats (encoding the oligo-leucine stretch in the signal sequence), tends to cross-hybridize with a number of unrelated genes, we used a 0.29-kb segment of rat cDNA encoding Gln33-Ser128 of prepro-orexin as a probe (1). Approximately one million clones from a human genomic library (CLONTECH) were screened by plaque hybridization with this cDNA probe. We isolated several clones, and one of the longest clones, lambda ghLig72-7, was analyzed further. We subcloned the 4.9-kb BamHI fragment of lambda ghLig72-7 insert into the pBluescript SKII(+) vector (Stratagene), which we termed pghLig72Bam, and subjected it to further characterization by standard procedures. DNA sequencing was performed with Thermo Sequenase (Amersham Pharmacia Biotech) and analyzed with LI-COR 4000L or IR4200 DNA sequencer following the manufacturer's instructions.

Genomic Southern Blot Analysis-- A membrane that contains human genomic DNA digested with designated restriction enzymes was purchased from CLONTECH (Human GENO-BLOT; catalog number 7700-1). The 544-bp PstI fragment of human prepro-orexin gene was labeled by the random priming method with [alpha 32P]dCTP to a specific activity of 5 × 108 cpm/mg and used as a probe. The membrane was incubated at 65 °C in a solution containing 1 M NaCl, 1% SDS, 150 mg/ml salmon sperm DNA, and 5 ng/ml probe. The membrane was finally washed in a solution containing 0.1× SSC (1× SSC = 0.15 M NaCl and 0.015 M sodium citrate) and 0.1% SDS at 50 °C and subjected to autoradiography at -80 °C for 48 h.

Primer Extension Analysis-- An infrared dye (IRD41)-labeled primer 5'-GTAGCCGGGAAAGGAGATGTCTGTGGTGG-3', which is complementary to position 72 to 100 of human prepro-orexin gene, was hybridized to 1 µg of human whole brain poly(A+) RNA (purchased from CLONTECH) in a solution containing 80% formamide, 400 mM NaCl, 10 mM EDTA, 40 mM PIPES (pH 6.4) at 30 °C. The hybridized RNA/primer was precipitated with ethanol and then subjected to reverse transcription with avian myeloblastosis virus reverse transcriptase. The same primer was also used for dideoxy sequencing reaction with Thermo Sequenase (Amersham Pharmacia Biotech) using lambda ghLig72-7 DNA as a template. The samples were analyzed by 4000L DNA sequencer (LI-COR).

Cloning of Human Prepro-orexin cDNA-- Human cDNA encoding prepro-orexin was cloned by the 3'-rapid amplification of cDNA ends method using human hypothalamus Marathon-ready cDNA (CLONTECH; catalog number 7429-1) as a template following the manufacturer's instruction. We made an oligonucleotide, 5'-ACATCTCCTTTCCCGGCTACCCCAC-3', which corresponds to nucleotides 81-105 of human prepro-orexin gene (5'-untranslated region of human prepro-orexin mRNA) and used it as a specific primer. We performed the polymerase chain reaction using this primer and adaptor primer (AP-1 primer; CLONTECH) under the following conditions: 30 cycles at 94 °C for 1 min, 60 °C for 1 min, and 70 °C for 1 min. A discrete 0.6-kb product containing the correct cDNA sequence was obtained and subcloned into pCR2.1 vector (Invitrogen). The cDNA sequence was determined by sequencing the products obtained from three independent 3'-rapid amplification of cDNA ends reactions with a DNA sequencer (LI-COR IR4200) using T7 primer and M13 reverse primer.

Transgenic Mice with Human Prepro-orexin-nlacZ Fusion Gene-- We performed polymerase chain reaction reaction using cloned human prepro-orexin gene as a template with two oligonucleotide primers, 5'-GCAGCGGCCATTCCTTGG-3' and 5'-AAGTCGACGGTGTCTGGCGCTCAGGGTG-3'. The product corresponded to position -118 to 122 of human prepro-orexin gene shown in Fig. 2 and had an artificial SalI site at the 3'-end. We digested this fragment with PstI and SalI and ligated it to the 1.6-kb PstI fragment of the cloned prepro-orexin gene (from -1.7 kb to 72 bp shown in Fig. 2). This DNA fragment was then ligated to BamHI-PstI (-3.15 --1.7 kb) fragment of the gene. The resulting DNA fragment, which has a 3.15-kb 5'-flanking region and the whole length of the 5'-noncoding region, was used as the promoter that directs expression of the cloned Escherichia coli lacZ gene with an inserted SV40 antigen nuclear localization signal (nlacZ), derived from pnlacF (8). The 3'-end of nlacZ was ligated to murine protamine-1 (mPrm1) gene fragment (from +95 relative to the transcription start site to +625), which includes part of exon 1 and all of intron 1 and exon 2, including the poly(A+) adenylation signal and site.

The resulting gene fragment free of vector sequence was isolated and injected into fertilized mouse eggs to generate transgenic founder animals. The presence and copy numbers of the transgene was identified by tail blot (9). Animals from these lines were examined by beta -galactosidase histochemical technique to assess transgene expression in the tissues.

LacZ Histochemical and Immunohistochemical Staining-- The mice were perfused via the heart with phosphate-buffered saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.3). Tissue fragments were further fixed for 60 min at 4 °C in the same fixative buffer. They were then rinsed three times with a solution containing 0.1 M phosphate buffer (pH 7.3), 2 mM MgCl2, 0.01% sodium deoxycholate, and 0.02% Nonidet P-40. The staining reaction was then performed by incubating the tissue fragments for 16-24 h at 37 °C in a solution containing 0.1 M phosphate buffer (pH 7.5), 2 mM MgCl2, 0.01% sodium deoxycholate, 0.02% Nonidet P-40, 1 mg/ml X-gal, 5 mM K3Fe(CN)6, and 5 mM K4Fe(CN)6. Post fixation was performed for 24-48 h in 10% formalin. Tissues were dehydrated and embedded in paraffin for sectioning.

For immunohistochemical staining, coronal sections of brain (40µm) were incubated for 35 min in 0.6% hydrogen peroxide to eliminate endogenous peroxide activity. Sections were rinsed in phosphate buffer and incubated for 30 min in Tris-buffered saline containing 3% normal goat serum and 0.25% Triton X-100. Thereafter, sections were incubated with rabbit polyclonal anti-orexin antibody (1) or anti-melanin-concentrating hormone (MCH) antibody diluted 1/2000 in Tris-buffered saline containing 1% normal goat serum and 0.25% Triton X-100 overnight at 4 °C. The primary antibody was localized with the avidin-biotin system (Vector Laboratories). Bound peroxidase was visualized by incubating sections with 0.01 M imidazole acetate buffer containing 0.05% 3,3'-diaminobenzidine tetrahydrochloride and 0.005% hydrogen peroxide.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Structure and Sequence of Human Prepro-orexin Gene and Its Transcript-- By screening a human genomic library (constructed in lambda EMBL3 SP6/T7 vector) with rat prepro-orexin cDNA probe, we cloned a recombinant lambda  phage clone lambda ghLig72-7, which has an approximately 18-kb insert that contains the whole length of human prepro-orexin gene. We subcloned the 4.9-kb BamHI fragment of lambda ghLig72-7 insert into the pBluescript SKII(+) vector (Stratagene), which we termed pghLig72Bam, and subjected it to further analyses. Structural organization of the human prepro-orexin gene and mRNA are shown in Fig. 1. We also cloned a cDNA for human prepro-orexin by 3'-rapid amplification of cDNA ends to determine the sequence of prepro-orexin mRNA.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 1.   A, structural organization of human prepro-orexin gene and mRNA. Exons are indicated by filled boxes. The structural organization of the mRNA is presented above the scheme of the gene structure. The translated region is shown by a box. The coding sequences for mature orexin-A and orexin-B are indicated by a filled box and a hatched box, respectively. The putative cleavage site for the secretory signal sequence is indicated by an arrow. B, diagram of orexin-nlacZ transgene. mPrm1, murine protamine 1 fragment that contains part of exon 1, all of intron 1, and exon 2, including the polyadenylation signal and site.

To locate the transcription initiation sites, we performed primer extension analysis using poly(A+) RNA from whole human brain or control yeast tRNA. Primer extension analysis with a 29-mer oligonucleotide primer complementary to the 5'-untranslated region (positions 23 to 51 upstream from the putative translation initiation site) revealed that the main transcription initiation site is at nucleotide 1 in Fig. 2. Although there is a TATAAA sequence in position 5-10, this result suggests that this TATA box-like sequence is nonfunctional. However, there is a minor signal at positions 33-35 (27-29 bases down stream of TATAAA sequence), implying the possible existence of an additional transcription initiation site. Human prepro-orexin gene lacks a typical CCAAT box. A potential site for the promoter region was predicted to start at position -291 by BCM Gene Finder web site.2 This program also ignores the TATAAA sequence in position 5-10.


View larger version (110K):
[in this window]
[in a new window]
 
Fig. 2.   Complete nucleotide sequence of human prepro-orexin gene cloned in phLig72Bam. The exon sequence is shown in capital letters, whereas introns and flanking sequences are shown in lowercase letters. Nucleotide residues are numbered positively, starting at the transcription initiation site determined by the primer extension analysis shown in Fig. 4 and negatively in the 5'-flanking sequence. Alu repeat elements are indicated by dashed underlines. The deduced amino acid sequence for prepro-orexin is shown under the nucleotide sequence of the translated region. Amino acid residues are numbered beginning with the initiative methionine residue. The sequences of mature orexin-A and orexin-B are underlined. The consensus sequence for the branch site of the intron is double-underlined. The poly(A+) signal (AATAAA) is indicated by thin underline. The nucleotide sequence has been submitted to GenBankTM (accession number AF118885).

The restriction enzyme map and the structural organization of the human prepro-orexin gene are schematically shown in Fig. 1. The complete nucleotide sequence of the structural gene and the 5'- and 3'-flanking regions determined from the results of primer extension analysis and the cDNA sequence are shown in Fig. 2. The pghLig72Bam insert contains a 3149-bp 5'-flanking region, a 1432-bp structural gene, and a 364-bp 3'-flanking region. The structural gene consists of two exons (143 and 473 bp) and one intron (816 bp). Southern blots of human genomic DNA were probed with the 544-bp PstI fragment of lambda ghLig72-7, which contains a part of intron 1 and exon 2. Single EcoRI (>23 kb), HindIII (7.0 kb), BamHI (4.9 kb), and PstI (0.55 kb) fragments of the genomic DNA hybridized with the probe, indicating that the cloned DNA is an authentic copy of the genomic DNA (Fig. 3).


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 3.   Southern blot analysis of human DNA with cloned human prepro-orexin gene fragment as a probe. Each lane contains 5 µg of digested human genomic DNA. The membrane was hybridized with a 544-bp PstI fragment of lambda ghLig72-7 insert. The positions of HindIII fragments of l-DNA are shown as molecular weight markers.

The intron 1 starts and ends with the consensus sequence for the 5'-end (KAG/GTRA) and 3'-end (YnNYAG/G, n = 10~12) of U2-type GT-AG introns (10), respectively, and has a putative branch site (CTRAY) at nucleotides 549-553 (CTGAT) (Fig. 2).

A BLAST (blastn) search of the GenBankTM data bases with the sequence presented in Fig. 3 failed to find a significantly similar sequence, except for several highly repetitive elements of the primate Alu family (nucleotides -2414 to -2143, -1916 to -1640, -1627 to -1343, -1292 to-1004, and -885 to -613) (searched with CENSOR Web Server3). These regions show 64-85% nucleotide identity with the consensus sequence of human Alu repeat.

Comparison of the gene and cDNA sequences, together with the results form the primer extension analysis (Fig. 4), suggest that human prepro-orexin mRNA, which is 616 nucleotides long excluding the poly(A+) tail, is encoded by two exons distributed over 1432 base pairs of the human genome (Figs. 1 and 2). The 5'-most ATG codon of the cDNA (nucleotides 123-125) was preceded by an in-frame stop codon (TGA; nucleotides 108-110), and the sequence around this initiation codon conformed well to Kozak's rules (11). The open reading frame starting with this ATG encodes a 131-residue polypeptide, human prepro-orexin (Fig. 2). The 5'-untranslated region and the first 7 residues of the secretory signal sequence correspond to the 143-bp first exon. The 473-bp second exon contains the remaining portion of the open reading frame and the 102-bp 3'-untranslated region. Thus, the remaining portion of the signal sequence (residues 8-33) and pro-orexin are encoded in exon 2 (Fig. 2).


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 4.   Mapping of sites of transcription initiation by primer extension method. An infrared dye (IRD41)-labeled primer (5'-GTAGCCGGGAAAGGAGATGTCTGTGGTGG-3') was hybridized with 1 µg of human brain poly(A+) RNA or 30 µg of yeast tRNA. The hybridized primer/RNA was extended with reverse transcriptase. The same primer was used for DNA sequencing with Thermo Sequenase using lambda ghLig72-7 as a template. These samples were analyzed simultaneously by a DNA sequencer (LI-COR). Asterisks show the transcription start site.

Structure and Sequence of Human Prepro-orexin-- The first 33 amino acids of human prepro-orexin exhibited characteristics of a secretory signal sequence: a hydrophobic core followed by residues with small polar side chains (12). The SignalP Server web site4 predicted that Ala33-Gln34 was the most likely site for signal sequence cleavage. The orexin-A sequence starts with Gln34, which is presumably cyclized enzymatically into the N-terminal pyroglutamyl residue by transamidation (13, 14). Thus, the mature peptide directly follows the signal peptide cleavage site. The last residue of the mature peptide is followed by Gly67, which presumably serves as an NH2 donor for C-terminal amidation by the sequential actions of peptidylglycine monooxygenase and peptidylamidoglycolate lyase (15, 16). As expected, Gly67 is followed by a pair of basic amino acid residues, Lys68-Arg69, which constitutes a recognition site for prohormone convertases (17). The last residue of the sequence of orexin-B, Met96 residue, is again followed by Gly-Arg-Arg. These observations suggest that human orexin-A and -B are also C-terminally amidated like their counterparts in the rodent.

The predicted human orexin-A sequence was identical to rodent/bovine orexin-A. Human orexin-B had two amino acid substitutions compared with the rodent sequence. Overall, the human prepro-orexin sequences were 83% identical to the rat counterpart (1). The majority of amino acid substitutions were found in the C-terminal part of the precursor, which appears unlikely to encode for another bioactive peptide.

Expression of beta -Galactosidase Gene in Transgenic Mice-- A fragment of human prepro-orexin gene, which contains a 3.15-kb 5'-flanking region and the whole length of the 5'-noncoding region of exon 1, was fused to the modified E. coli lacZ gene, which has an SV40 T antigen nuclear localization signal (nlacZ) (8) (Fig. 1). We generated transgenic mice using this construct as a transgene. A total of six lines bearing the transgene were examined, and lacZ expression could be detected in three of these (Table I).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Characterization of six hOX-nlacZ-transgenic lines

The lacZ staining showed that the transgene was highly specifically expressed in the LHA/subthalamic region in two lines (Table I), suggesting that this fragment contains all the necessary elements for appropriate expression in these regions (Fig. 5). We observed that the neurons expressing the transgene were only a subset of the neurons expected to stain. Generally, only 30-50% of neurons containing immunoreactive orexin were stained by beta -galactosidase histochemical technique. All of the lacZ-positive neurons in the LHA contained immunoreactive orexins (Fig. 5).


View larger version (112K):
[in this window]
[in a new window]
 
Fig. 5.   Expression of E. coli beta -galactosidase gene in the brain of the human orexin-nlacZ fusion gene-transgenic mice line A3 (Table I), visualized by lacZ histochemistry. The expression of transgene is observed in orexin-containing neurons (A and B) but not in MCH-containing neurons (C and D) in the LHA. A, visualization of neurons containing E. coli beta -galactosidase directed by cloned human orexin gene promoter in the brain of transgenic mice. The coronal section of brain stained with lacZ histochemistry showing the bilateral and symmetrical distribution of labeled neurons within and around the LHA (stained blue). No detectable signal other than background was generated in transgene negative controls (not shown). The section was then stained with anti-orexin antibody (golden brown). B, higher magnification of section shown in A. Note that all lacZ-positive neurons (stained blue) contain immunoreactive orexins (stained brown). C, the lacZ-stained section was doubly stained with anti-MCH antibody. D, higher magnification of section shown in C. Note that MCH neurons do not overlap with lacZ-positive neurons.

Line D5 showed ectopic expression of lacZ in several regions that do not express orexins, including the arcuate nucleus, periventricular nucleus, and preoptic nuclei (Table I). This ectopic expression was only observed in line D5 and might be because of a positional effect. We could not observe any ectopic expression of transgene other than the eutropic expression in the LHA in line A3 and line J2 (Table I).

We also examined whether MCH-containing neurons, which are also known to be exclusively located in the LHA and adjacent regions, express the transgene or not. As shown in Fig. 5, MCH-positive neurons did not show lacZ activity, suggesting that this promoter does not direct expression to the MCH neurons. We could not observe any positive lacZ staining in tissues outside the brain.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Recent studies have identified several neuropeptide and receptor systems in the hypothalamus that are critical in the regulation of body weight (18). The LHA has long been considered essential in regulating food intake and body weight, because cell specific lesions of this region can result in decreased food intake and body weight (2), and this region contains glucose-sensing neurons (4).

We recently identified a family of neuropeptides, orexins, which are localized exclusively in neurons in the LHA. Orexins increase food intake when administered intracerebroventricularly. The neurons containing orexins (orexin neurons) diffusely innervate the entire brain, including monosynaptic projections to the cerebral cortex, limbic system, and brain stem (5-7). Therefore, orexin neurons may be ideally positioned to regulate cognitive, motivational, emotional, and autonomic aspects of food intake and body weight regulation.

Orexin neurons are shown to be highly specifically localized within and around the LHA in rodents and humans (1, 5-7). These observations suggest the existence of molecular mechanisms by which orexin expression is highly restricted to distinct populations of neurons in these regions. To examine these mechanisms, we first determined the structure of the human prepro-orexin gene and its transcript.

The human prepro-orexin mRNA was predicted to encode a 131-residue precursor peptide. The human prepro-orexin gene consists of two exons and one intron distributed over 1432 bp (Fig. 1, 2). The 143-bp exon 1 includes the 5'-untranslated region and the coding region that encodes the first 7 residues of the secretory signal sequence. Exon 2 contains the remaining portion of the open reading frame and the 3'-untranslated region. The predicted human orexin-A sequence was identical to rodent/bovine/porcine orexin-A. Human orexin-B had two amino acid substitutions compared with the rodent sequence, and one amino acid substitution as compared with the porcine sequence (Fig. 2). Considering the difference in species, the structures of both orexins are strikingly conserved. This suggests the important physiological roles of orexins.

To evaluate the function of the cloned human prepro-orexin gene fragment, we generated transgenic mice using human orexin gene-nlacZ fusion gene. This construct utilizes the human prepro-orexin gene fragment, which contains the 3,149-bp 5'-flanking region and 122-bp 5'-noncoding region of exon 1 to drive the nlacZ gene as a reporter protein (Fig. 1). We found that this gene fragment is sufficient to direct the expression of human prepro-orexin mRNA in the LHA and adjacent regions (Table I, Fig. 5). This finding suggests that this genomic fragment contains all the necessary elements for appropriate expression of the gene. However, we observed that the neurons expressing the transgene were only a subset of the orexin-containing neurons (Fig. 5). Generally, only 30-50% of neurons containing immunoreactive orexins were stained by beta -galactosidase histochemistry. This phenomenon has also been described for hsp68-lacZ and dopamine beta  hydroxylase-lacZ transgene and is referred to as incomplete penetrance (8, 19).

On the other hand, neurons containing MCH, which are also known to be localized exclusively in the LHA, did not express lacZ in the transgenic mice (Fig. 5). This observation suggests that this promoter specifically directs expression to orexin neurons, and orexin neurons and MCH neurons are distinct neuronal populations.

Transgenic line D5 showed ectopic expression in several regions, which may be because of a positional effect (Table I). Alternatively, there may be other necessary elements to ensure the proper gene expression in other genomic regions. In this case, ectopic expression would be eliminated by the inclusion of additional DNA for the endogenous gene, leading to valuable insights into the regulatory mechanism of the endogenous gene.

In any case, the 3.2-kb human prepro-orexin promoter we used in this study was sufficient to direct expression of the exogenous gene in orexin-producing neurons in transgenic mice. Therefore, this promoter might be useful to examine the consequences of the expression of exogenous molecules in orexin neurons of transgenic mice, thereby manipulating the cellular environment in vivo. This genomic fragment will also be useful for the targeted ablation of orexin neurons by using it as a promoter that drives toxin expression (20).

Prepro-orexin mRNA was shown to be up-regulated under fasting conditions, indicating that these neurons somehow sense the nutritional status of the animal. We have found that orexin gene expression is influenced by plasma glucose and leptin levels.5 Human prepro-orexin nlacZ transgenic mice will also be useful to examine the molecular mechanisms by which orexin gene expression is regulated.

    ACKNOWLEDGEMENTS

We are grateful to Drs. N. A. Tritos and T. Maratos-Flier for providing us anti-MCH antiserum. We thank Dr. W. Gray for reading our manuscript.

    FOOTNOTES

* This work was supported in part by grants from the University of Tsukuba Project Research and by the Ministry of Education, Science, and Culture of Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF118885.

§ To whom correspondence should be addressed: Tel.: 81-298-53-3276; Fax: 81-298-53-3039; E-mail: stakeshi{at}md.tsukuba.ac.jp.

2 http://defrag.bcm.tmc.edu:9503/genefinder/gf.html.

3 http://charon.lpi.org/~server/censor.html.

4 http://www.cbs.dtu.dk/services/SignalP/.

5 T. Sakurai, T. Moriguchi, and Yamanaka, A., unpublished observation.

    ABBREVIATIONS

The abbreviations used are: LHA, lateral hypothalamic area; MCH, melanin-concentrating hormone; kb, kilobase pair(s); bp, base pair(s); PIPES, 1,4-piperazinediethanesulfonic acid; nlacZ, E. coli beta -galactosidase gene with a nuclear localization signal.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R., M., Tanaka, H., Williams, S., C., Richardson, J. A., Kozlowski, G. P., Wilson, S., Arch, J. R., Buckingham, R. E., Haynes, A. C,., Carr, S. A., Annan, R. S., McNulty, D. E., Liu, W. S., Terrett, J. A., Elshourbagy, N. A., Bergsma, D. J., and Yanagisawa, M. (1998) Cell 92, 573-585[Medline] [Order article via Infotrieve]
  2. Bernardis, L. L., and Bellinger, L. L. (1996) Neurosci. Biobehav. Rev. 20, 189-287[CrossRef][Medline] [Order article via Infotrieve]
  3. Bernardis, L. L., and Bellinger, L. L. (1993) Neurosci. Biobehav. Rev. 17, 141-193[Medline] [Order article via Infotrieve]
  4. Oomura, Y. (1980) Handbook of the Hypothalamus, pp. 557-620, Marcel Dekker, Inc., New York
  5. Date, Y., Ueta, Y., Ymamashita, H., Yamaguchi, H., Matsukura, S., Kangawa, K., Sakurai, T., Yanagisawa, M., and Nakazato, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 748-753[Abstract/Free Full Text]
  6. Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., and Kilduff, T. S. (1998) J. Neurosci. 18, 9996-10015[Abstract/Free Full Text]
  7. Elias, C. F., Saper, C. B., Maratos-Flier, E., Tritos, N. A., Lee, C., Kelly, J., Tatro, J. B., Hoffmann, G. E., Ollmann, M. M., Barsh, G. S., Sakurai, T., Yanagisawa, M., and Elmquist, J. K. (1998) J. Comp. Neurol. 402, 442-459[CrossRef][Medline] [Order article via Infotrieve]
  8. Mercer, E. H., Hoyle, G. W., Kapur, R. P., Brinster, R. L., and Palmiter, R. D. (1991) Neuron 7, 703-716[Medline] [Order article via Infotrieve]
  9. Brinster, R. L., Chen, H. Y., Trumbauer, M., Senear, A. W., Warren, R., and Palmiter, R. D. (1981) Cell 27, 223-231[CrossRef][Medline] [Order article via Infotrieve]
  10. Sharp, P. A., and Burge, C. B. (1997) Cell 91, 875-879[Medline] [Order article via Infotrieve]
  11. Kozak, M. (1984) Nucleic Acids Res. 12, 857-874[Abstract]
  12. von Heijne, G. (1986) Nucleic Acids Res. 14, 4683-4690[Abstract]
  13. Bateman, A., Solomon, S., and Bennett, H. P. J. (1990) J. Biol. Chem. 265, 22130-22136[Abstract/Free Full Text]
  14. Busby, W. H., Jr., Quackenbush, G. E., Humm, J., Youngblood, W. W., and Kizer, J. S. (1987) J. Biol. Chem. 262, 8532-8536[Abstract/Free Full Text]
  15. Bradbury, A. F., and Smyth, D. G. (1991) Trends Biochem. Sci. 16, 112-115[CrossRef][Medline] [Order article via Infotrieve]
  16. Eipper, B. A., Milgram, S. L., Husten, E. J., Yun, H. Y., and Mains, R. E. (1993) Protein Sci. 2, 489-497[Abstract/Free Full Text]
  17. Rouille, Y., Dugay, S. J., Lund, K., Furuta, M., Gong, Q., Lipkind, G., Oliva, A. A., Jr., Chan, S. J., and Steiner, D. F. (1995) Front. Neuroendocrinol. 16, 322-361[CrossRef][Medline] [Order article via Infotrieve]
  18. Flier, J. S., and Maratosflier, E. (1998) Cell 92, 437-440[Medline] [Order article via Infotrieve]
  19. MacGowen, R., Campbell, R., Peterson, A., and Sapienza, C. (1989) Genes Dev. 3, 1669-1676[Abstract]
  20. Palmiter, R. D., Behringer, R. R., Quaife, C. J., Maxwell, F., Maxwell, I. H., and Brinster, R. L. (1987) Cell 50, 435-443[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.